AUS
NZ
UK
CA
USA
IND
Stockhead’s health and biotech expert, Tim Boreham, returns to the studio for another episode of the Health Kick Podcast. In this installment, Boreham engages in a conversation with Dr. Michael Thurn, the Managing Director at PharmAust (ASX:PAA).
PharmAust has recently taken significant steps in its efforts to address the challenges associated with amyotrophic lateral sclerosis (ALS) by submitting a request for orphan medicinal product designation (OMPD) to the European Medicines Agency (EMA) for its lead drug, monepantel. Originally developed for veterinary applications, monepantel has exhibited promising potential in slowing the progression of ALS, a neurodegenerative disease that significantly impacts motor function and quality of life.
The drug is currently navigating through the clinical development phase, with PharmAust preparing to enter an adaptive Phase 2/3 clinical trial in the United States. This pivotal trial is anticipated to commence in late 2024, marking a crucial milestone in the company's efforts to bring monepantel to the forefront of ALS treatment options. The trial will likely involve a comprehensive evaluation of the drug's efficacy and safety, further elucidating its potential benefits for patients battling this debilitating condition.
The discussion delves into the intricacies of monepantel's development, including the rationale behind pursuing an orphan designation, which could expedite the regulatory process and provide incentives for bringing this treatment to market. Dr. Thurn sheds light on the importance of orphan drug status, emphasizing how it can facilitate research and development for rare diseases that often struggle to attract attention from larger pharmaceutical companies due to limited commercial viability.
Listeners will gain insights into the broader landscape of ALS research, the challenges faced by companies working on treatments for rare diseases, and the unique position PharmAust holds in this competitive field. The podcast also touches on the potential implications of successful trials for patients living with ALS and the impact that monepantel could have on their lives.
As the conversation unfolds, Boreham and Dr. Thurn explore the company’s strategic vision and ongoing efforts to innovate within the biotech sector. The dialogue not only highlights PharmAust’s advancements with monepantel but also addresses the critical need for effective therapies in the realm of neurodegenerative diseases.
This episode of the Health Kick Podcast provides a platform for listeners to better understand the complexities of drug development in the biotechnology sector and the promising avenues being pursued by PharmAust in the fight against ALS.
